By Nadine M. Hasenecz

The FDA concludes that the cholesterol-lowering drugs simvastatin (Zocor),ezetimibe (Zetia), and Vytorin (ezetimibe/simvastatin) are not likely to increase cancer risk.

According to data from a French study, patients with unresectable metastatic colorectal cancer who experience a chemotherapy-free interval (CFI) following first-line chemotherapy have shorter durations of disease control(DDC)and progression-free survival (PFS) compared with patients who begin maintenance therapy immediately.

According to a multi-institutional study, terminally ill cancer patients are more likely to seek hospice care and less likely to pursue aggressive end-of-life (EOL) treatment if the medical team supports their spiritual needs.